Social Media Ideas for Caribou Biosciences

UCSD, IGI Partnership Expands CRISPR Innovation Across Health, Agriculture, and the Environment

UC San Diego has joined the Innovative Genomics Institute as its fourth UC partner, expanding collaboration to develop next-generation genome-editing technologies that address majo...

Bicistornic Vectors + piggyBac = Improved Antibody Cell Line Production

To produce stable cell lines for monoclonal antibody production, manufacturers typically use the piggyBac transposon system. For larger, multi-specific antibodies that have payload...

Nobel Laureate Jennifer Doudna enters AI protein design arena

Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene-editing, is dipping her toes into a new, buzzy fiel...

Precision BioSciences: Promising HBV Editing Evidence

RNAV8 Bio Joins ARPA-H Team to Pioneer Programmable RNA Medicines

The PROPEL program aims to control gene expression through RNA structure, building logic-gated RNA therapies that switch on only where and when intended, without altering the genom...

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years. 

BaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic Development

Unlike prediction-based approaches, Broken String Biosciences says BaseMap ABE generates genome-wide data directly from biologically relevant cells, providing researchers with clea...

CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO

Scribe Therapeutics’ IPO will support a pipeline led by a genetic medicine that represses expression of its target gene without making permanent changes. Common chronic cardiometab...

CrisprBits is using CRISPR to build faster tests for drug-resistant infections

The Bengaluru-based company has built three CRISPR platforms covering molecular diagnostics, gene editing and disease modelling, and is commercialising the diagnostics one first.

Cellares and Sonoma Biotherapeutics Agree to Automate Engineered Treg Cell Therapy Manufacturing

Cellares plans to translate the manufacturing of SonomaBio’s SBT-77-7101 onto its Cell Shuttle and automate in-process and release testing through the Cell Q quality control syste...

Fur Real: Biotech Startup Eliminates Major Dog Allergen in Beagle Pups Using CRISPR

The puppies represent a key first step towards addressing canine allergenicity and mark potentially a significant advance in veterinary biotechnology. The post Fur Real: Biotech St...

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds

In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.

NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy

The collaboration brings together Synastra’s expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix’s propri...

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027

Cellogen Therapeutics is developing CAR-T cell therapies for blood cancers in India

The Delhi company designs and manufactures its own cell and gene therapies and is preparing a first clinical trial with Christian Medical College, Vellore.

Moonwalk reloads with $70M and new RNAi prospects for obesity

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

Genetic medicine luminaries launch new center for personalized therapies

A team of veteran scientists from elite institutions has come together to form a new center dedicated to the crafting of personalized genetic medicines, adding to the growing list...

In vivo CAR T Industry Leaps Forward with Challenges Ahead

The emerging new class of in vivo CAR T therapeutics is seen by regulators as gene therapies with risks of off-target effects to patients. Manufacturers need to rise to the challen...

Allogeneic CAR T Company Prepares to Widen Access to Patients

An allogeneic CAR T-cell therapy company is planning a pivotal Phase III randomized-control trial, hoping their products can reach more patients and help those who can’t access aut...

Genomes to bioreactors: Saudi Arabia’s gene editing oncology push

Saudi Arabia is pairing gene editing breakthroughs with new biomanufacturing capacity, from CRISPR oncology therapies to CDMOs like Lifera, as it builds a full biotech pipeline. Th...

Scribe secures $129M in a rare gene editing IPO

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotech companies that have gone public in 2026.

Genome-Scale CRISPRi Atlas Maps Gene Function Across Human iPSCs

A genome-scale CRISPRi atlas maps transcriptional consequences for 11,692 gene perturbations across more than 2.5 million human iPSCs. The resource reveals regulators of metabolism...

BrainChild hauls in $116M to make cell therapies for childhood brain cancers

Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.